Obstetrics & Gynecology

Skip Navigation LinksHome > September 2005 - Volume 106 - Issue 3 > Efficacy of a New Low-Dose Oral Contraceptive With Drospiren...
Obstetrics & Gynecology:
doi: 10.1097/01.AOG.0000175834.77215.2e
Original Research

Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder

Yonkers, Kimberly A. MD1; Brown, Candace RN, PharmD2; Pearlstein, Teri B. MD3; Foegh, Marie MD, DSc4; Sampson-Landers, Carole MD4; Rapkin, Andrea MD5

Collapse Box

Abstract

Objective: To compare the efficacy of a new low-dose oral contraceptive pill (OCP) formulation with placebo in reducing symptoms of premenstrual dysphoric disorder.

Methods: This multicenter, double-blind, randomized clinical trial consisted of 2 run-in and 3 treatment cycles with daily symptom charting; 450 women with symptoms of premenstrual dysphoric disorder were randomized to either placebo or an OCP formulation containing drospirenone 3 mg and ethinyl estradiol 20 μg. Hormones were administered for 24 days, followed by 4 days of inactive pills (24/4).

Results: Scores on the total Daily Record of Severity of Problems decreased by –37.49 in the drospirenone/ethinyl estradiol group and by –29.99 in the placebo group (adjusted mean difference –7.5, 95% confidence interval [CI] –11.2 to –3.8; P < .001 by rank analysis of covariance). Mood symptom scores were reduced by –19.2 and –15.3 in active-treatment and placebo groups, respectively (adjusted mean difference –3.9, 95% CI –5.84 to –2.01; P = .003); physical symptom scores were reduced by –10.7 and –8.6 in active-treatment and placebo groups, respectively (adjusted mean difference –2.1, 95% CI –3.3 to –0.95; P < .001); and behavioral symptom scores were reduced by –7.7 and –6.2 in active-treatment and placebo groups, respectively (adjusted mean difference –1.5, 95% CI –2.251 to –0.727; P < .001). Response, defined as a 50% decrease in daily symptom scores, occurred in 48% of the active-treatment group and 36% of the placebo group (relative risk 1.7, 95% CI 1.1 to 2.6; P = .015) and corresponds to a number-needed-to-treat of 8 patients.

Conclusion: A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 μg improves symptoms associated with premenstrual dysphoric disorder.

Level of Evidence: I

© 2005 The American College of Obstetricians and Gynecologists

Login

 

Looking for ABOG articles? Visit our ABOG MOC II collection. The selected Green Journal articles are free from October through December

ACOG MEMBER SUBSCRIPTION ACCESS

If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.

Article Tools

Share

Article Level Metrics